Corrigendum to "Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study" [Endocrine Practice 30 (2024) 424-430]
- PMID: 39945693
- DOI: 10.1016/j.eprac.2025.01.006
Corrigendum to "Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study" [Endocrine Practice 30 (2024) 424-430]
Erratum for
-
Corrigendum to "Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study" [Endocrine Practice 30 (2024) 424-430].Endocr Pract. 2024 Sep;30(9):898. doi: 10.1016/j.eprac.2024.06.012. Epub 2024 Jul 17. Endocr Pract. 2024. PMID: 39023469 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources